Alnylam Pharma (ALNY) Ownership - Who Owns Alnylam Pharma?

1,437 Followers

Alnylam Pharma (ALNY) Ownership Overview

0.23% Insiders

43.78% Mutual Funds

31.64% Other Institutional Investors

21.86% ETFs

2.49% Public Companies and

Individual Investors

The ownership structure of Alnylam Pharma (ALNY) stock is a mix of institutional, retail, and individual investors. Approximately 97.28% of the company’s stock is owned by Institutional Investors, 0.23% is owned by Insiders, and 2.49% is owned by Public Companies and Individual Investors.

The ownership structure of Alnylam Pharma (ALNY) stock is a mix of institutional, retail, and individual investors. Approximately 75.42% of the company’s stock is owned by Institutional Investors, 0.23% is owned by Insiders, and 21.86% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date	Name	Activity	Value
Apr 07, 2026	Melissa Mclaughlin	xxxxxxxxxxxxx	$519014
Mar 06, 2026	Yvonne Greenstreet	xxxxxxxxxxxxx	$947581
Mar 06, 2026	Jeffrey V. Poulton	xxxxxxxxxxxxx	$797351
Mar 06, 2026	Pushkal Garg	xxxxxxxxxxxxx	$745984

Show More Insider Trading Activity >

Recent Hedge Fund Trading Activity

Date	Firm	Activity	Value
Mar 31, 2024	Dodge & Cox	xxxxxxxxxxxxx	$638331940
Mar 31, 2024	Bridgewater Associates, Lp	xxxxxxxxxxxxx	$35268095
Mar 31, 2024	Fisher Asset Management Llc	xxxxxxxxxxxxx	$2000109
Mar 31, 2024	Driehaus Capital Management Llc	xxxxxxxxxxxxx	$19727131

Show More Hedge Fund Trading Activity >

Top Shareholders

# of Shares	Type	% Holding	Value
12,170,796	Institution	9.12%	3,632,739,190
11,242,175	Institution	8.42%	3,355,564,394
8,024,520	Institution	6.01%	2,395,158,730
5,751,255	Institution	4.31%	1,716,634,592
4,254,883	Institution	3.19%	1,269,997,478
3,744,659	Institution	2.80%	1,117,705,818
2,436,710	Institution	1.83%	727,309,201
2,392,493	Institution	1.79%	714,111,311
2,246,395	Institution	1.68%	670,503,980
2,218,165	Institution	1.66%	662,077,889

Top Mutual Fund Holders

# of Shares	Type	% Holding	Value
11,242,175	Institution	8.42%	3,355,564,394
8,024,520	Institution	6.01%	2,395,158,730
3,744,659	Institution	2.80%	1,117,705,818
2,436,710	Institution	1.83%	727,309,201
2,392,493	Institution	1.79%	714,111,311
2,246,395	Institution	1.68%	670,503,980
2,218,165	Institution	1.66%	662,077,889
2,051,779	Institution	1.54%	612,414,996
1,604,154	Institution	1.20%	478,807,886
1,478,741	Institution	1.11%	441,374,614

Top ETF Holders

Holder	# of Shares	Type	% Holding	Value
Vanguard Total Stock Market ETF	4,217,053	Institution	3.16%	1,395,296,326
Invesco QQQ Trust	2,868,895	Institution	2.15%	856,307,780
Vanguard Mid-Cap ETF	2,864,993	Institution	2.15%	947,940,234
Vanguard Growth ETF	1,564,640	Institution	1.17%	517,692,437
Vanguard Extended Market ETF	1,482,298	Institution	1.11%	490,447,939
Vanguard Mid-Cap Growth ETF	1,008,744	Institution	0.76%	333,763,127
iShares Biotechnology ETF	968,113	Institution	0.73%	282,718,039
iShares Russell Mid-Cap Growth ETF	835,422	Institution	0.63%	243,968,287
Capital Group Growth ETF	604,690	Institution	0.45%	176,587,621
Invesco NASDAQ 100 ETF	549,089	Institution	0.41%	160,350,461

FAQ

Who Owns Alnylam Pharmaceuticals (ALNY)?

According to the latest TipRanks data, approximately 31.64% of the company's stock is held by institutional investors, 0.23% is held by insiders, and 2.49% is held by retail investors.

What percentage of Alnylam Pharmaceuticals (ALNY) stock is held by institutional investors?

According to the latest TipRanks data, approximately 31.64% of Alnylam Pharmaceuticals (ALNY) stock is held by institutional investors.

What percentage of Alnylam Pharmaceuticals (ALNY) stock is held by retail investors?

According to the latest TipRanks data, approximately 2.49% of Alnylam Pharmaceuticals (ALNY) stock is held by retail investors.

Who owns the most shares of Alnylam Pharmaceuticals (ALNY)?

Vanguard owns the most shares of Alnylam Pharmaceuticals (ALNY).

What is the significance of the ownership structure for a publicly traded company?

The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.